A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)
NCT04771507
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Interventions
DRUG:
Ibrutinib
Sponsor
Jeanette Lundin